您的购物车当前为空
别名 ZINC205721785, PF-06281355, PF 06281355
PF-1355 (PF 06281355) 是一种有效的 MPO 抑制剂。PF-1355用于血管炎的研究。


为众多的药物研发团队赋能,
让新药发现更简单!
PF-1355 (PF 06281355) 是一种有效的 MPO 抑制剂。PF-1355用于血管炎的研究。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 189 | 现货 | |
| 2 mg | ¥ 271 | 现货 | |
| 5 mg | ¥ 442 | 现货 | |
| 10 mg | ¥ 738 | 现货 | |
| 25 mg | ¥ 1,180 | 现货 | |
| 50 mg | ¥ 2,230 | 现货 | |
| 100 mg | ¥ 3,220 | 现货 | |
| 200 mg | ¥ 4,420 | 现货 | |
| 500 mg | 待询 | 现货 | |
| 1 mL x 10 mM (in DMSO) | ¥ 493 | 现货 |
PF-1355 相关产品
| 产品描述 | PF-1355 (PF 06281355) is a selective 2-thiouracil mechanism-based MPO inhibitor. PF-1355 is used for treatment of vasculitic diseases. |
| 体外活性 | PF-1355 inhibits MPO activity in phorbol ester-stimulated human neutrophils as measured by taurine chlorination (EC50=1.47 μM) as well as lipopolysaccharide-treated human blood measuring residual MPO activity (EC50=2.03 μM) [1]. |
| 体内活性 | Oral administration of PF-1355 reduces plasma MPO activity, vascular edema, neutrophil recruitment, and elevates circulating cytokines. In a model of anti-glomerular basement membrane disease, albuminuria and chronic renal dysfunction are completely suppressed by PF-1355 treatment [1]. |
| 别名 | ZINC205721785, PF-06281355, PF 06281355 |
| 分子量 | 321.35 |
| 分子式 | C14H15N3O4S |
| CAS No. | 1435467-38-1 |
| Smiles | COc1ccc(OC)c(c1)-c1cc(=O)[nH]c(=S)n1CC(N)=O |
| 密度 | 1.43 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 55 mg/mL (171.15 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.22 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容